Codexis (CDXS) News Today → Does this make you sick? (From Allegiance Gold) (Ad) Free CDXS Stock Alerts $3.61 -0.16 (-4.24%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | americanbankingnews.comCodexis, Inc. (NASDAQ:CDXS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 15, 2024 | marketbeat.comCodexis, Inc. (NASDAQ:CDXS) Given Consensus Recommendation of "Moderate Buy" by AnalystsCodexis, Inc. (NASDAQ:CDXS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. TheMay 14, 2024 | globenewswire.comCodexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual MeetingMay 11, 2024 | americanbankingnews.comCodexis (NASDAQ:CDXS) Stock Passes Above Two Hundred Day Moving Average of $2.83May 4, 2024 | finance.yahoo.comCodexis First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comCodexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 3, 2024 | finance.yahoo.comCodexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comCodexis (NASDAQ:CDXS) Given "Buy" Rating at BenchmarkBenchmark reissued a "buy" rating and issued a $9.00 price target on shares of Codexis in a research report on Friday.May 2, 2024 | finance.yahoo.comCodexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic AdvancesMay 1, 2024 | markets.businessinsider.comHere's what to expect from Codexis's earningsMay 1, 2024 | msn.comCodexis Q1 2024 Earnings PreviewApril 26, 2024 | finance.yahoo.comWith 74% institutional ownership, Codexis, Inc. (NASDAQ:CDXS) is a favorite amongst the big gunsApril 19, 2024 | finance.yahoo.comCodexis, Inc. (CDXS)April 18, 2024 | globenewswire.comCodexis to Report First Quarter 2024 Financial Results on May 2April 11, 2024 | marketbeat.comBaillie Gifford & Co. Cuts Stock Position in Codexis, Inc. (NASDAQ:CDXS)Baillie Gifford & Co. cut its holdings in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,419,093 shares of the biotechnology company's stock after selling 630,474 sharApril 11, 2024 | globenewswire.comCodexis Appoints Carole Cobb, MBA, to Strategic Advisory BoardApril 2, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 296,704 Shares of Codexis, Inc. (NASDAQ:CDXS)Assenagon Asset Management S.A. cut its holdings in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 16.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,456,739 shares of the biotechnology company'March 31, 2024 | marketbeat.comCodexis, Inc. (NASDAQ:CDXS) Sees Large Decline in Short InterestCodexis, Inc. (NASDAQ:CDXS - Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 2,290,000 shares, a decrease of 9.8% from the February 29th total of 2,540,000 shares. Based on an average daily trading volume, of 631,800 shares, the days-to-cover ratio is currently 3.6 days.March 30, 2024 | finance.yahoo.comFavourable Signals For Codexis: Numerous Insiders Acquired StockMarch 26, 2024 | marketbeat.comCodexis, Inc. (NASDAQ:CDXS) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Codexis, Inc. (NASDAQ:CDXS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned aMarch 19, 2024 | seekingalpha.comAQST,CDXS and STI are among after hour moversMarch 12, 2024 | marketbeat.comGSA Capital Partners LLP Invests $786,000 in Codexis, Inc. (NASDAQ:CDXS)GSA Capital Partners LLP acquired a new position in Codexis, Inc. (NASDAQ:CDXS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 416,059 shares of the biotechnology cMarch 8, 2024 | marketbeat.comFmr LLC Boosts Position in Codexis, Inc. (NASDAQ:CDXS)Fmr LLC boosted its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 153.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,335,580 shares of the biotechnology company's stock after acquiring an additional 2,626,400March 2, 2024 | marketbeat.comFederated Hermes Inc. Decreases Stake in Codexis, Inc. (NASDAQ:CDXS)Federated Hermes Inc. lessened its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 44.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,398,031 shares of the biotechnology company's stockMarch 1, 2024 | msn.comBenchmark raises Codexis to buy; cites Q4 earnings, guidanceMarch 1, 2024 | msn.comBenchmark Upgrades Codexis (CDXS)February 29, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Codexis (CDXS)February 29, 2024 | finance.yahoo.comCodexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finanznachrichten.deCodexis, Inc.: Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 29, 2024 | finance.yahoo.comQ4 2023 Codexis Inc Earnings CallFebruary 29, 2024 | marketbeat.comCodexis (NASDAQ:CDXS) Raised to "Buy" at BenchmarkBenchmark upgraded shares of Codexis from a "hold" rating to a "buy" rating in a research report on Thursday.February 28, 2024 | benzinga.comRecap: Codexis Q4 EarningsFebruary 28, 2024 | msn.comCodexis GAAP EPS of -$0.10 beats by $0.04, revenue of $26.56M beats by $7.63MFebruary 28, 2024 | finance.yahoo.comCodexis Inc (CDXS) Reports Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comCodexis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | theglobeandmail.comBiotech Rallied Strongly On Exclusive Licensing AgreementFebruary 27, 2024 | marketwatch.comCodexis Shares Up 31% on Roche Licensing AgreementFebruary 27, 2024 | msn.comCodexis Q4 2023 Earnings PreviewFebruary 27, 2024 | marketbeat.comCodexis, Inc. (NASDAQ:CDXS) Position Increased by Acadian Asset Management LLCAcadian Asset Management LLC raised its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 25.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 949,916 shares of the biotechnology company'sFebruary 26, 2024 | msn.comCodexis stock climbs 11% on Roche licensing deal for DNA ligasesFebruary 26, 2024 | globenewswire.comCodexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with RocheFebruary 26, 2024 | globenewswire.comCodexis to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 20, 2024 | finance.yahoo.comCodexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory BoardFebruary 20, 2024 | globenewswire.comCodexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory BoardFebruary 17, 2024 | marketbeat.comCodexis, Inc. (NASDAQ:CDXS) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its position in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 34.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,049,567 shares of the biotechnology company's stock afteFebruary 16, 2024 | money.usnews.comCodexis Inc.February 14, 2024 | globenewswire.comCodexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28February 14, 2024 | marketbeat.comCodexis (NASDAQ:CDXS) Shares Pass Above 200-Day Moving Average of $2.25Codexis (NASDAQ:CDXS) Stock Price Crosses Above 200 Day Moving Average of $2.25February 3, 2024 | marketbeat.comCodexis, Inc. (NASDAQ:CDXS) Shares Sold by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC cut its stake in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 92.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 43,203 shares of the biotechnology company's stock after sellingFebruary 2, 2024 | msn.comKLIC, CLFD and CDXS are among after hour movers Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Email Address This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade. Register for the imminent briefing here. CDXS Media Mentions By Week CDXS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDXS News Sentiment▼0.260.42▲Average Medical News Sentiment CDXS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDXS Articles This Week▼32▲CDXS Articles Average Week Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SMTI News IMMP News AKBA News EDAP News SENS News JYNT News VMD News DSGN News GLUE News AXGN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDXS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
